We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of sorafenib in advanced thyroid cancer.
- Authors
Gupta-Abramson, Vandana; Troxel, Andrea B; Nellore, Anoma; Puttaswamy, Kanchan; Redlinger, Maryann; Ransone, Kathy; Mandel, Susan J; Flaherty, Keith T; Loevner, Laurie A; O'Dwyer, Peter J; Brose, Marcia S
- Abstract
Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases inhibited by sorafenib, including Raf kinase, vascular endothelial growth factor receptors, platelet-derived growth factor receptor, and RET tyrosine kinases, we conducted an open-label phase II trial to determine the efficacy of sorafenib in patients with advanced thyroid carcinoma.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 29, p4714
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.3279